These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10810957)

  • 41. [On some pharmacobiological characteristics of a new estrogen derivative (3-tetrahydropyranyl ether of 17-beta-estradiol)].
    Plancher G
    Minerva Ginecol; 1971 Sep; 23(17):671-8. PubMed ID: 5131894
    [No Abstract]   [Full Text] [Related]  

  • 42. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.
    Al-Baghdadi O; Ewies AA
    Climacteric; 2009 Apr; 12(2):91-105. PubMed ID: 19117185
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Estrogen therapy in older patients with recurrent urinary tract infections: a review.
    Rozenberg S; Pastijn A; Gevers R; Murillo D
    Int J Fertil Womens Med; 2004; 49(2):71-4. PubMed ID: 15188831
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pulsed estrogen therapy: from cellular mode of action to tissue effects.
    Al-Azzawi F
    Climacteric; 2002 Jun; 5 Suppl 2():27-31. PubMed ID: 12482108
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Herbal alternatives as substitutes for hormone therapy in urogenital atrophy: scientific evidence is needed.
    Bouchard C
    Menopause; 2008; 15(1):12-3. PubMed ID: 18000474
    [No Abstract]   [Full Text] [Related]  

  • 46. Urogenital atrophy: diagnosis, sequelae, and management.
    Keil K
    Curr Womens Health Rep; 2002 Aug; 2(4):305-11. PubMed ID: 12150759
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
    Menopause; 2009; 16(5):907-22. PubMed ID: 19436225
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of oral estriol on urogenital symptoms, vaginal cytology, and plasma hormone level in postmenopausal women.
    Manonai J; Theppisai U
    J Med Assoc Thai; 2001 Apr; 84(4):539-44. PubMed ID: 11460966
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Directly comparing routes of administration and types of hormone therapy on risk markers for breast cancer.
    Pru JK
    Menopause; 2007; 14(4):611. PubMed ID: 17471109
    [No Abstract]   [Full Text] [Related]  

  • 50. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women.
    Labrie F; Cusan L; Gomez JL; Côté I; Bérubé R; Bélanger P; Martel C; Labrie C
    Menopause; 2009; 16(1):30-6. PubMed ID: 18820592
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [17 beta-estradiol. as a patch. An elixir of youth as a prescription for the menopausal woman].
    Taeron C
    Rev Infirm; 2002 Mar; (79):45-7. PubMed ID: 11979678
    [No Abstract]   [Full Text] [Related]  

  • 52. Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms.
    Speroff L; Haney AF; Gilbert RD; Ellman H;
    Menopause; 2006; 13(3):442-50. PubMed ID: 16735941
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of raloxifene and low-dose percutaneous 17beta-estradiol on menopause symptoms and endometrium--a randomized controlled trial.
    Valiati B; Capp E; Edelweiss MI; de Freitas FM; Wender MC
    Maturitas; 2009 Jan; 62(1):81-4. PubMed ID: 19097715
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects on climacteric symptoms, bone and lipoprotein metabolism of hormone replacement therapy delivered by estradiol-releasing intravaginal rings: a pilot study.
    Farish E; Barnes JF; Rankin M; Hart DM
    Climacteric; 2003 Sep; 6(3):211-20. PubMed ID: 14567769
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The "Genitourinary Syndrome of Menopause": A Leap Forward?
    Vieira-Baptista P; Marchitelli C; Haefner HK
    J Low Genit Tract Dis; 2015 Oct; 19(4):362-3. PubMed ID: 26083333
    [No Abstract]   [Full Text] [Related]  

  • 56. Optimizing the dose of hormone replacement therapy.
    Rice VM
    Int J Fertil Womens Med; 2002; 47(5):205-10. PubMed ID: 12469707
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study.
    Cicinelli E; de Ziegler D; Alfonso R; Nicoletti R; Bellavia M; Colafiglio G
    Fertil Steril; 2005 Jun; 83(6):1859-63. PubMed ID: 15950667
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Postmenopausal vaginal atrophy correlates with decreased estradiol and body mass index and does not depend on the time since menopause.
    Repse-Fokter A; Takac I; Fokter SK
    Gynecol Endocrinol; 2008 Jul; 24(7):399-404. PubMed ID: 18645712
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaginal ring delivering estradiol and progesterone: a possible alternative to relieve climacteric symptoms.
    Ben-Chetrit A; Hochner-Celnikier D; Lindenberg T; Zacut D; Shimonovitz S; Gelber H; Spitz IM
    Isr Med Assoc J; 2005 May; 7(5):302-6. PubMed ID: 15909462
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Estrasorb.
    Chiechi LM
    IDrugs; 2004 Sep; 7(9):860-4. PubMed ID: 15470604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.